The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults.

Compare signs and symptoms of urinary tract infections at 14 days after treatment compared with signs and symptoms before treatment [ Time Frame: 14 days after treatment ] [ Designated as safety issue: No ]

ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.

Other Names:

MK0826

Invanz

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patient has a complicated urinary tract infection

Patient has acute pyelonephritis with fever, flank pain, pus in the urine, and positive urine culture

Patient is indian and 18 years of age or greater.

Exclusion Criteria:

Patient had a kidney transplant

Patient had been given antibiotic therapy for condition

Patient had poor liver function

Patient has complete obstruction of urinary tract

Patient has history of serious allergy to antibiotics and multivitamins

Patient is pregnant

Patient not likely to respond to 10 to 14 days of antibiotic therapy

Patient not likely to survive 4 week study period

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00379951